345 related articles for article (PubMed ID: 29844277)
1. Potential Application of the CRISPR/Cas9 System against Herpesvirus Infections.
Chen YC; Sheng J; Trang P; Liu F
Viruses; 2018 May; 10(6):. PubMed ID: 29844277
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.
van Diemen FR; Kruse EM; Hooykaas MJ; Bruggeling CE; Schürch AC; van Ham PM; Imhof SM; Nijhuis M; Wiertz EJ; Lebbink RJ
PLoS Pathog; 2016 Jun; 12(6):e1005701. PubMed ID: 27362483
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Kaposi's sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells.
Haddad CO; Kalt I; Shovman Y; Xia L; Schlesinger Y; Sarid R; Parnas O
Virol J; 2021 Mar; 18(1):56. PubMed ID: 33731154
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
Liang Z; Qin Z; Riker AI; Xi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):1400-1405. PubMed ID: 33092788
[TBL] [Abstract][Full Text] [Related]
5. Targeted Mutagenesis of Guinea Pig Cytomegalovirus Using CRISPR/Cas9-Mediated Gene Editing.
Bierle CJ; Anderholm KM; Wang JB; McVoy MA; Schleiss MR
J Virol; 2016 Aug; 90(15):6989-6998. PubMed ID: 27226370
[TBL] [Abstract][Full Text] [Related]
6. Rapid CRISPR/Cas9-Mediated Cloning of Full-Length Epstein-Barr Virus Genomes from Latently Infected Cells.
Yajima M; Ikuta K; Kanda T
Viruses; 2018 Apr; 10(4):. PubMed ID: 29614006
[TBL] [Abstract][Full Text] [Related]
7. Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR/Cas9-mediated targeting of a major viral latent protein.
Ju E; Li T; Ramos da Silva S; Markazi A; Gao SJ
J Med Virol; 2021 Aug; 93(8):5065-5075. PubMed ID: 33942339
[TBL] [Abstract][Full Text] [Related]
8. Mutagenesis and Genome Engineering of Epstein-Barr Virus in Cultured Human Cells by CRISPR/Cas9.
Yuen KS; Chan CP; Kok KH; Jin DY
Methods Mol Biol; 2017; 1498():23-31. PubMed ID: 27709566
[TBL] [Abstract][Full Text] [Related]
9. Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived Epstein-Barr Virus Strains.
Kanda T; Furuse Y; Oshitani H; Kiyono T
J Virol; 2016 May; 90(9):4383-93. PubMed ID: 26889033
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9, a powerful tool to target human herpesviruses.
van Diemen FR; Lebbink RJ
Cell Microbiol; 2017 Feb; 19(2):. PubMed ID: 27860066
[TBL] [Abstract][Full Text] [Related]
11. RNA-guided gene editing of the murine gammaherpesvirus 68 genome reduces infectious virus production.
Foreman HC; Kirillov V; Paniccia G; Catalano D; Andrunik T; Gupta S; Krug LT; Zhang Y
PLoS One; 2021; 16(6):e0252313. PubMed ID: 34086743
[TBL] [Abstract][Full Text] [Related]
12. Development of Genome Editing Approaches against Herpes Simplex Virus Infections.
Zhang I; Hsiao Z; Liu F
Viruses; 2021 Feb; 13(2):. PubMed ID: 33671590
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and therapy of herpesvirus infections].
Abb J
Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):107-20. PubMed ID: 2986378
[TBL] [Abstract][Full Text] [Related]
14. CRISPR Interference Efficiently Silences Latent and Lytic Viral Genes in Kaposi's Sarcoma-Associated Herpesvirus-Infected Cells.
Brackett K; Mungale A; Lopez-Isidro M; Proctor DA; Najarro G; Arias C
Viruses; 2021 Apr; 13(5):. PubMed ID: 33924938
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research.
Wang D; Wang XW; Peng XC; Xiang Y; Song SB; Wang YY; Chen L; Xin VW; Lyu YN; Ji J; Ma ZW; Li CB; Xin HW
Cancer Gene Ther; 2018 Jun; 25(5-6):93-105. PubMed ID: 29691470
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay.
Nishiwaki M; Fujimuro M; Teishikata Y; Inoue H; Sasajima H; Nakaso K; Nakashima K; Sadanari H; Yamamoto T; Fujiwara Y; Ogawa N; Yokosawa H
J Med Virol; 2006 Dec; 78(12):1635-42. PubMed ID: 17063511
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge.
Lee C
Molecules; 2019 Apr; 24(7):. PubMed ID: 30959782
[TBL] [Abstract][Full Text] [Related]
18. Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9.
Oh HS; Neuhausser WM; Eggan P; Angelova M; Kirchner R; Eggan KC; Knipe DM
Elife; 2019 Dec; 8():. PubMed ID: 31789594
[TBL] [Abstract][Full Text] [Related]
19. Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR/Cas9 and CRISPR/CasX Systems.
Karpov DS; Demidova NA; Kulagin KA; Shuvalova AI; Kovalev MA; Simonov RA; Karpov VL; Snezhkina AV; Kudryavtseva AV; Klimova RR; Kushch AA
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499174
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-Based Genome Editing of HSV.
Velusamy T; Gowripalan A; Tscharke DC
Methods Mol Biol; 2020; 2060():169-183. PubMed ID: 31617178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
